{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:11:01Z","timestamp":1778217061662,"version":"3.51.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the 12-week effectiveness and safety of dydrogesterone monotherapy versus estradiol\u2013dydrogesterone (E2\/DYD) combination therapy in women with perimenopausal symptoms in a real-world clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 150 women treated at a tertiary gynecological outpatient clinic between July 2022 and January 2025 (dydrogesterone: n=60; E2\/DYD: n=90). The primary endpoint was change in the Kupperman Menopause Index (KMI) from baseline to week 12. Repeated measures were analyzed using linear mixed-effects models. Secondary outcomes included clinical response (\u226550% KMI reduction), endometrial thickness change, and adverse events. Continuous outcomes were evaluated using adjusted linear regression models, and binary outcomes were analyzed using Firth penalized logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 12 weeks, KMI decreased by 8.0 \u00b1 6.6 points in the dydrogesterone group and 12.5 \u00b1 7.4 points in the E2\/DYD group (adjusted mean difference \u22124.51, 95% CI \u22126.90 to \u22122.12; p&amp;lt;0.001). Clinical response occurred in 31.5% and 51.2% of participants, respectively (adjusted OR 2.08, 95% CI 1.02\u20134.45; p=0.042). Improvements in vasomotor and mood-related symptoms were more pronounced in the combination group. Endometrial thickness increased modestly in the E2\/DYD group (+0.60 mm), with week-12 mean values remaining within physiologic ranges. Any adverse event was reported in 11.1% versus 31.7% of participants (adjusted OR 3.55, 95% CI 1.29\u20139.77; p=0.014), predominantly mild and self-limited events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort, E2\/DYD combination therapy was associated with greater short-term symptom reduction compared with dydrogesterone monotherapy. Although adverse events were more frequent with combination therapy, they were generally mild and clinically manageable, and no concerning endometrial safety signals were observed over 12 weeks. As a retrospective observational study, causal conclusions cannot be drawn, and these findings should be regarded as hypothesis-generating. They provide real-world contextual evidence to inform clinical discussions around hormone therapy selection in perimenopausal care, pending confirmation in prospective randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1816597","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:45:02Z","timestamp":1778215502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of dydrogesterone monotherapy versus estradiol\u2013dydrogesterone combination therapy in perimenopausal women: a real-world cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuaiting","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gynecology, Ganzhou Women and Children\u2019s Health Care Hospital","place":["GanZhou, JiangXi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Ganzhou Women and Children\u2019s Health Care Hospital","place":["GanZhou, JiangXi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Ganzhou Women and Children\u2019s Health Care Hospital","place":["GanZhou, JiangXi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3362","article-title":"Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging","volume":"97","author":"Harlow","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa764","article-title":"The menopause transition: Signs, symptoms, and management options","volume":"106","author":"Santoro","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24140","article-title":"Management of menopausal symptoms: A review","volume":"329","author":"Crandall","year":"2023","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of The North American Menopause Society","volume":"30","year":"2023","journal-title":"Menopause (New York NY)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2025.2585487","article-title":"International Menopause Society (IMS) recommendations and key messages on women\u2019s midlife health and menopause","volume":"28","author":"Panay","year":"2025","journal-title":"Climacteric"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beem.2012.09.004","article-title":"Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills","volume":"27","author":"Sitruk-Ware","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestins","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.03.077","article-title":"Dydrogesterone increases allopregnanolone in selected brain areas and in serum of female rats","volume":"89","author":"Pluchino","year":"2008","journal-title":"Fertility Sterility"},{"key":"B10","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1210\/jcem-13-6-688","article-title":"Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices","volume":"13","author":"Kupperman","year":"1953","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1002\/9781119513469","volume-title":"Applied Longitudinal Analysis","author":"Fitzmaurice","year":"2011"},{"key":"B12","volume-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.035","article-title":"Vasomotor symptom relief versus unwanted effects: Role of estrogen dosage","volume":"118","author":"Ettinger","year":"2005","journal-title":"Am J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.6542","article-title":"The women\u2019s health initiative randomized trials and clinical practice: A review","volume":"331","author":"Manson","year":"2024","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051438","article-title":"A new hope for woman with vasomotor symptoms: Neurokinin B antagonists","volume":"14","author":"Meczekalski","year":"2025","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American menopause society","volume":"29","year":"2022","journal-title":"Menopause (New York NY)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/cmt.5.1.26.35","article-title":"Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17beta-estradiol combined with sequential 5\u201320 mg dydrogesterone","volume":"5","author":"Ferenczy","year":"2002","journal-title":"Climacteric"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(00)00176-6","article-title":"Endometrial safety of continuous combined hormone replacement therapy with 17beta-oestradiol (1 or 2 mg) and dydrogesterone","volume":"37","author":"Bergeron","year":"2001","journal-title":"Maturitas"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000284450.51264.31","article-title":"Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: A randomized controlled trial","volume":"110","author":"Bachmann","year":"2007","journal-title":"Obstetrics Gynecology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1055\/s-0045-1809186","article-title":"Progestogens in menopausal hormone therapy: A double-edged sword","volume":"43","author":"Ylikorkala","year":"2025","journal-title":"Semin Reprod Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet (London England)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13098-025-01664-1","article-title":"The effects of transdermal estrogens combined with Medroxyprogesterone Acetate on cardiovascular disease risk factors in postmenopausal women: A meta-analysis of randomized controlled trials","volume":"17","author":"Zhou","year":"2025","journal-title":"Diabetol Metab Syndrome"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1816597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:45:12Z","timestamp":1778215512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1816597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":22,"alternative-id":["10.3389\/fendo.2026.1816597"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1816597","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1816597"}}